How the concept of reusability helps in programming medicine’s final frontier?

In a future where drug development is increasingly programmable, the concept of reusability could revolutionize healthcare.

Jorge Conde explores how programmable medicines, inspired by SpaceX’s reusable rockets, can transform the way we innovate in medicine. He also discusses how the FDA is embracing this shift towards more flexible and transparent evaluations of such therapies.

Programmable medicines represent a significant advancement in drug development.

They involve reusable components that allow for different applications, much like reusable rockets that deliver various payloads to new destinations.

This approach has the potential to reduce costs and expand horizons in medical innovation.

The FDA is adopting an approach similar to that of FAA’s aviation safety—rigorous yet adaptive—for evaluating and approving programmable medicines.

They have launched their own office for therapeutic products and piloted Operation Warp Speed for rare diseases, signaling their readiness to embrace this shift.

Programmable medicine can potentially transform each stage of traditional drug development by reusing components for different applications.

For instance, successful gene therapy could pave the way for delivering different genes to other cell types for various diseases, thereby reducing time spent on approvals.

Programmable medicines like gene therapy can reuse components like the delivery vehicles used to target specific cells while swapping out the genetic cargo. The next mission uses the same rocket to deliver a different payload to a new destination. – Jorge Conde

We are seeing meaningful innovation in terms of the kinds of medicines we can make and the FDA is appropriately trying to find ways to remain their rigor because again they have an extraordinarily high obligation to ensure safety and efficacy in patients but move hopefully more quickly. – Jorge Conde

The concept of reusability in programmable medicine mirrors SpaceX’s reusable rockets where only the payload changes but not the vehicle delivering it.

Once a ‘rocket’ or delivery system gets approved, most legwork would be done, significantly speeding up subsequent processes.

The FDA is actively looking for ways to review therapies that reuse components rigorously and adaptively.

The establishment of the new Office of Therapeutic Products signifies their recognition for innovation in the kinds of medicines being made, and their commitment to speeding up the process.